[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345462-105":59,"doc-detail-345462-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","liquid-biopsy-differentiation-of-pancreatic-cancer-from-non-cancerous-pancreatic-disease-using-dielectrophoresis-recovered-nanoparticles-carrying-cell-free-dna-and-protein-biomarkers","Liquid Biopsy Differentiation of Pancreatic Cancer From Non-Cancerous Pancreatic Disease Using Dielectrophoresis-Recovered Nanoparticles Carrying Cell-Free DNA and Protein Biomarkers","","Cancer-derived extracellular vesicle (EV) nanoparticles contain valuable biomarkers but are hard to retrieve from plasma, limiting EV-based diagnostics in clinical workflows. This study presents dielectrophoresis (DEP) nanoparticle recovery that purifies nanoparticles from undiluted plasma and quantifies associated biomarkers. A single device integrates nanoparticle recovery with on-chip fluorescent staining for cell-free DNA and Glypican-1. In a blinded cohort, combined DNA/protein biomarkers distinguish pancreatic cancer from benign conditions, including cysts, pancreatitis, and precancerous low-grade IPMN lesions, achieving sensitivity 0.92, specificity 0.83, and AUC 0.93.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/liquid-biopsy-differentiation-of-pancreatic-cancer-from-non-cancerous-pancreatic-disease-using-dielectrophoresis-recovered-nanoparticles-carrying-cell-free-dna-and-protein-biomarkers/345462/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/liquid-biopsy-differentiation-of-pancreatic-cancer-from-non-cancerous-pancreatic-disease-using-dielectrophoresis-recovered-nanoparticles-carrying-cell-free-dna-and-protein-biomarkers/345462.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is EV-based liquid biopsy difficult in clinical settings?","Question",{"text":112,"@type":113},"Cancer-derived EV nanoparticles carry biomarkers but are difficult to recover from plasma due to small size and low buoyant density, making retrieval and analysis challenging for clinical use.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the DEP-based method improve nanoparticle recovery?",{"text":117,"@type":113},"The technique uses dielectrophoresis (DEP) nanoparticle recovery to purify nanoparticles from undiluted plasma and then quantifies associated biomarkers.",{"name":119,"@type":110,"acceptedAnswer":120},"How well do the DNA and protein biomarkers differentiate pancreatic cancer from benign pancreatic disease?",{"text":121,"@type":113},"In a blinded cohort, the biomarkers differentiated pancreatic cancer from benign diseases with sensitivity 0.92, specificity 0.83, and AUC 0.93, increasing to 0.97 for patients over 50.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345462,1791167434,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Small  \n[www.small-journal.com](www.small-journal.com)  \nRESEARCH ARTICLE   \nLiquid Biopsy Differentiation of Pancreatic Cancer From Non-Cancerous Pancreatic Disease Using Dielectrophoresis-Recovered Nanoparticles Carrying Cell-Free DNA and Protein Biomarkers  \nAnna Malakian1   Augusta Modestino1  Jesus Bueno1  Archana Machireddy2  Jason Ware1, 2    \nSean Hamilton1, 2   Ella Stimson1, 2   Sarah Mitchell1, 2   Joshua C. Saldivar1, 3   Ashley R. Woodfin4   Corey M. Dambacher4  Kyle Gustafson1, 2   Delaney Shea1, 2   Srivathsan Ranganathan1    \nMehrzad Sasanpour1   Christian Ross1   Dove Keith5  Jeong Youn Lim6   Xubo Song1   Scott M. Lippman7   Rosalie Sears5, 8, 9   Terry Morgan10  Michael Heller1   Stuart D. Ibsen1, 2   \n1 Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA  2 Department of Biomedical Engineering, School of Medicine, Oregon Health and Science University, Portland, Oregon, USA  3 Division of Oncological Sciences, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA  4 RyboDyn Inc., San Diego, California, USA  5 Brenden-Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, Oregon, USA  6 Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA  7Moores Cancer Center, University of California San Diego, San Diego, California, USA  8 Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA  9 Knight Cancer Institute, Oregon Health and Science University, Portland,  \nOregon, USA  10 Pathology & Laboratory Medicine, Oregon Health and Science University, Portland, Oregon, USA Correspondence: Stuart D. Ibsen ([ibsen@ohsu.edu](ibsen@ohsu.edu))  \nReceived: 26 February 2025  Revised: 6 January 2026  Accepted: 7 January 2026  \nKeywords: dielectrophoresis (DEP) | extracellular vesicles | liquid biopsy | microfluidics | pancreatic cancer detection  \nABSTRACT  \nCancer-derived extracellular vesicle (EV) nanoparticles carry important biomarkers but are difficult to recover from plasma, making EV-based diagnostics a challenge for clinical settings. Here, we demonstrate nanoparticle-based detection of pancreatic cancer using dielectrophoresis (DEP) nanoparticle recovery technology, which purifies nanoparticles from undiluted plasma and quantifies associated biomarkers. We combined both nanoparticle recovery and biomarker quantification on a single device by simultaneously collecting cell-free DNA nanoparticles and EVs followed by on-chip biomarker fluorescent staining for DNA and Glypican-1. Using a blinded cohort, these biomarkers differentiated pancreatic cancer from benign pancreatic diseases, including cysts, pancreatitis, and precancerous low-grade intraductal papillary mucinous neoplasm (IPMN) lesions, with a sensitivity of 0.92, a specificity of 0.83, and an AUC of 0.93 . The AUC increased to 0.97 for patients over 50 years old. This is higher than the standard invasive endoscopic ultrasound-guided fine needle aspiration tissue biopsy procedure (AUC 0.79). This study is among the first demonstrating a combined threshold of DNA and protein levels that can distinguish pancreatic cancer from its precursor IPMN lesions. We also demonstrated the detection of early-stage pancreatic cancer and high-grade in situ precancerous lesions. This DEP-based technique shows that multiple types of cancer-derived nanoparticles can be quickly and easily recovered from plasma making it promising for future clinical diagnostics.  \n\n| Scott M. Lippman, Rosalie Sears, Terry Morgan, and Michael Heller contributed equally to this work.\u003Cbr>|\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.","cbCaiaxW6dhNnINE","https://ap.wps.com/l/cbCaiaxW6dhNnINE","pdf",5509385,16,"English","# Abstract\n# Introduction","[{\"question\":\"Why is EV-based liquid biopsy difficult in clinical settings?\",\"answer\":\"Cancer-derived EV nanoparticles carry biomarkers but are difficult to recover from plasma due to small size and low buoyant density, making retrieval and analysis challenging for clinical use.\"},{\"question\":\"How does the DEP-based method improve nanoparticle recovery?\",\"answer\":\"The technique uses dielectrophoresis (DEP) nanoparticle recovery to purify nanoparticles from undiluted plasma and then quantifies associated biomarkers.\"},{\"question\":\"How well do the DNA and protein biomarkers differentiate pancreatic cancer from benign pancreatic disease?\",\"answer\":\"In a blinded cohort, the biomarkers differentiated pancreatic cancer from benign diseases with sensitivity 0.92, specificity 0.83, and AUC 0.93, increasing to 0.97 for patients over 50.\"}]","Liquid Biopsy Differentiation of Pancreatic Cancer From Non-Cancerous Pancreatic Disease Using Dielectrophoresis-Recovered Nanoparticles Carrying Cell-Free DNA and Protein Biomarkers | PDF",1790057725,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40e786e4f7476f5e60e2418bf54fed28.webp",983,1283,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3a61546764359a43ccf73206a9f450b.webp",982,1281,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a65513577f0937c3623e418fe7c248c.webp",981,1280,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9fc9ddaeaa4de2c9f8c07ce518424829.webp",980,1279]